KSP

The Phage is a medical technology company specializing in the development of AI-driven solutions to predict postprandial blood glucose levels for type 2 diabetes patients. Its application analyzes biometric data and daily activities, empowering users with personalized health insights to make informed lifestyle changes.

Thermalytica specializes in research, development, and consulting services for heat insulating materials and heat shielding materials. It offers electron beam physical vapor deposition equipment and thermal barrier coating equipment, serving industries such as construction materials, plants, and home appliances.

Mira Robotics, Inc. is a Japanese company based in Kawasaki City that specializes in designing and developing a Robot as a Service (RaaS) platform. Founded in 2018, the company offers a range of services including robot development, robot intelligence, and cloud collaboration, enabling robots to be utilized in various fields. Through its innovative approach, Mira Robotics aims to enhance the functionality and accessibility of robotic technologies for diverse applications.

Melody International specializes in developing medical equipment for remote healthcare services. Its flagship product is a fetal monitoring device designed to assist doctors during challenging deliveries, featuring a fetal heart monitor, uterine contraction monitor, and a tablet with internet connectivity.

Metcela is a clinical-stage biotechnology company based in Kawasaki, Japan, developing fibroblast-based therapies for heart disease. Its approach uses VCAM-1–positive cardiac fibroblasts derived from a patient’s own heart to repair damaged tissue and reestablish a supportive microenvironment, rather than replacing cells. The lead program, MTC001, aims to restore heart function by promoting natural healing in preclinical studies. Metcela was founded in 2016.

AdipoSeeds develops a platelet-making system that generates platelets from mesenchymal stem cells without complex and costly gene transfer. The company aims to address global platelet shortages by enabling a future in which platelet-related treatments are cheaply and safely provided, supported by a new blood supply system. Its technology also leverages adipose-derived materials to produce fat-derived platelets for blood products and wound care medicine, positioning AdipoSeeds to serve biotechnology clients seeking innovative platelet-based solutions.

Luxonus is a medical device company focused on imaging technology that combines light and ultrasound to produce ultra-high-resolution 3D images of blood vessels and lymphatic networks. It develops a photoacoustic imaging platform designed for early detection and diagnosis of diseases, enabling clinicians to gain a comprehensive view of disease onset, progression, and recovery with non-invasive visualization and no radiation exposure.

Ampametry provides neuropsychiatric drugs with AMPA-PET technology. They offers central nervous system drug discovery business AMPA-PET technology.

Integral Geometry Science designs and develops measurement devices and software for image data processing and manufactures microwave mammography equipment and nondestructive inspection systems for lithium-ion batteries. Based in Kobe, Japan, the company focuses on inverse analysis of electromagnetic and scattered fields to advance measurement technology. Its microwave mammography solution aims to address the inverse scattering problem in high-density breasts, delivering clearer images that help distinguish breast cancer tissue from normal tissue and reduce patient radiation exposure and discomfort compared with conventional screening. The company serves medical imaging and non-destructive testing markets.

iXs develops AI-integrated robots for maintenance inspections in social and industrial infrastructure. They offer products and services from introduction to operation, aiming to solve customer issues and reduce human workload.

Integral Geometry Science designs and develops measurement devices and software for image data processing and manufactures microwave mammography equipment and nondestructive inspection systems for lithium-ion batteries. Based in Kobe, Japan, the company focuses on inverse analysis of electromagnetic and scattered fields to advance measurement technology. Its microwave mammography solution aims to address the inverse scattering problem in high-density breasts, delivering clearer images that help distinguish breast cancer tissue from normal tissue and reduce patient radiation exposure and discomfort compared with conventional screening. The company serves medical imaging and non-destructive testing markets.

StemRIM is a biotechnology company based in Ibaraki, Japan, founded in 2006, specializing in the development of regeneration-guided medicines for treating intractable diseases. The company focuses on innovative research and development of therapies that mobilize stem cells within the body to promote healing in various conditions, including epidermolysis bullosa, cerebral infarction, and myocardial infarction. StemRIM offers a range of products, including regeneration-inducing peptides and proteins, as well as therapeutic autologous cell collection devices and stem cell gene therapy technologies. The company aims to advance regenerative medicine by creating treatments that facilitate functional tissue regeneration without the need for external stem cell extraction.

Miraikikai, Inc. is a Japanese company specializing in the development, manufacturing, distribution, and maintenance of robotics and mechatronics products. Founded in 2004 and based in Takamatsu, Japan, the company originated from Kagawa University and aims to create intelligent mobile robots for professional use. Its product offerings include solar cleaning robots that utilize advanced artificial intelligence to efficiently clean solar panels at utility-scale plants without water, employing brushes and air blowers to remove dust and sand. Additionally, Miraikikai develops 3D Laser Sensors for various applications and provides technical consultation and development solutions, leveraging extensive research and experience in mechanical design and control technology to deliver high-quality, cost-effective solutions.

Metcela is a clinical-stage biotechnology company based in Kawasaki, Japan, developing fibroblast-based therapies for heart disease. Its approach uses VCAM-1–positive cardiac fibroblasts derived from a patient’s own heart to repair damaged tissue and reestablish a supportive microenvironment, rather than replacing cells. The lead program, MTC001, aims to restore heart function by promoting natural healing in preclinical studies. Metcela was founded in 2016.

Renascience is a research and development company focused on creating treatments for medical conditions and manufacturing pharmaceuticals. It develops and commercializes pharmaceuticals, medical devices, and software as a medical device that leverages artificial intelligence.

Cyfuse Biomedical specializes in developing tissue fabrication systems and cell-based products for global research institutions. It offers a robotic 3D BioFabrication system, producing various tissue grafts for therapeutic use, drug development, and research purposes. Founded in 2010, the company is headquartered in Tokyo, Japan.

StemRIM is a biotechnology company based in Ibaraki, Japan, founded in 2006, specializing in the development of regeneration-guided medicines for treating intractable diseases. The company focuses on innovative research and development of therapies that mobilize stem cells within the body to promote healing in various conditions, including epidermolysis bullosa, cerebral infarction, and myocardial infarction. StemRIM offers a range of products, including regeneration-inducing peptides and proteins, as well as therapeutic autologous cell collection devices and stem cell gene therapy technologies. The company aims to advance regenerative medicine by creating treatments that facilitate functional tissue regeneration without the need for external stem cell extraction.

CODE Meee is a fragrance company based in Yokohama, Japan, founded in 2017. It develops and manufactures scents and provides fragrance branding, marketing, and product planning services for individuals and businesses. The company combines data-driven scent recommendations with fragrance program planning and production, and operates an aroma subscription platform that delivers personalized perfumes aimed at improving mood and reducing stress as part of mental health support.

Rena Therapeutics Inc. is a biopharmaceutical company based in Tsukuba, Japan, specializing in the development of nucleic acid medicines aimed at treating various types of cancer and intractable diseases. Founded in January 2015, the company focuses on utilizing its proprietary Hetero-Duplex oligonucleotides technology to create novel drug delivery systems that target tumors more effectively than conventional drugs. Rena Therapeutics aims to address unmet medical needs by offering treatments for a range of conditions, including glioma, melanoma, acute and chronic leukemias, and lymphomas. The advantages of nucleic acid drugs, such as the ability to specifically target intracellular drug molecules and minimize side effects, position the company at the forefront of innovative therapeutic solutions in the pharmaceutical market.

Spectronix is a company dedicated to the development of innovative laser technologies and applications, specifically tailored for microprocessing and microfabrication. By focusing on advancements in laser technology, Spectronix aims to enhance manufacturing processes, offering faster processing speeds that vary according to the materials used. This efficiency allows manufacturers to achieve competitive pricing and reduced operational costs, positioning Spectronix as a key player in the laser technology sector.

Z-Works Inc. is a Tokyo-based technology company specializing in Internet of Things (IoT) solutions. Established in 2015, it develops a range of IoT devices, including sensors for monitoring, fire alarms, smart locks, and smart meters. The company also offers consulting services for proof of concept, as well as sensor packages tailored for specific applications. Its flagship product, the Z-Works Life Engine, is a cloud-based IoT platform that collects and analyzes data from devices equipped with communication protocols. This platform enables users to access data remotely via smartphones, facilitating improved care for elderly individuals in various settings, including care facilities and home environments. By providing innovative IoT solutions, Z-Works aims to alleviate the challenges faced by caregivers and enhance the quality of life for users.

Spectronix is a company dedicated to the development of innovative laser technologies and applications, specifically tailored for microprocessing and microfabrication. By focusing on advancements in laser technology, Spectronix aims to enhance manufacturing processes, offering faster processing speeds that vary according to the materials used. This efficiency allows manufacturers to achieve competitive pricing and reduced operational costs, positioning Spectronix as a key player in the laser technology sector.

Kringle Pharma is a Japanese biopharmaceutical company focused on the research and development of hepatocyte growth factor (HGF)–based protein medicines and NK4 therapies. The company aims to leverage HGF’s regenerative properties and NK4’s antiangiogenic activity to address organ repair and cancer indications. Its pipeline includes recombinant human HGF for acute renal failure, spinal cord injury, and CNS diseases, as well as recombinant NK4 and NK4 gene therapies for cancer. Founded in 2001, the company operates in the Japanese market.

Starsphere is a developer of a cloud-based Electronic Data Capture (EDC) system that focuses on transforming data collection, analysis, and utilization in the life sciences sector. The company's platform is designed to enhance IT services primarily for the healthcare industry, aiming to improve the efficiency and safety of medical treatments. By leveraging advanced technologies, Starsphere strives to enable healthcare professionals to deliver more effective and safer treatments to patients in a timely manner, aligning with its vision of advancing healthcare outcomes.

Stem Cell & Device Laboratory, Inc. is a research and development company based in Kyoto, Japan, focused on the manufacturing and sale of cells, devices, and integrated products that utilize cell materials for drug discovery applications. Founded in 2014, the company specializes in developing innovative scaffold materials that demonstrate functional and cell compatibility, particularly for studies involving pluripotent stem cells. By leveraging advanced micro-engineering and nanofabrication technologies, Stem Cell & Device Laboratory aims to contribute to advancements in cell application products that support the health and well-being of society.

Founded in Tokyo, Japan in 2007, Ipoca develops a digital platform that connects users with local retail stores, fostering economic revitalization and mobility.

Nanoegg is aiming to create a medical breakthrough from skin research and to realize medical care without the use of needles.

Founded in 2001, Fileforce is a Tokyo-based company offering secure cloud file services for businesses of all sizes. It enables enterprises to store, manage, access, and share files securely from anywhere using computers, tablets, or smartphones.

TMS Co., Ltd., established in 2005 and headquartered in Tokyo, Japan, is a clinical-stage biotechnology company. It specializes in developing drug candidates and medical technologies derived from academic research. TMS focuses on a unique group of small molecule compounds, known as SMTPs, which exhibit both thrombolytic and anti-inflammatory properties. The company's lead compound, TMS-007, is currently in a Phase IIa clinical trial for the treatment of acute ischemic stroke, in partnership with Biogen.

Rena Therapeutics Inc. is a biopharmaceutical company based in Tsukuba, Japan, specializing in the development of nucleic acid medicines aimed at treating various types of cancer and intractable diseases. Founded in January 2015, the company focuses on utilizing its proprietary Hetero-Duplex oligonucleotides technology to create novel drug delivery systems that target tumors more effectively than conventional drugs. Rena Therapeutics aims to address unmet medical needs by offering treatments for a range of conditions, including glioma, melanoma, acute and chronic leukemias, and lymphomas. The advantages of nucleic acid drugs, such as the ability to specifically target intracellular drug molecules and minimize side effects, position the company at the forefront of innovative therapeutic solutions in the pharmaceutical market.

Founded in 2011, Megakaryon is a Japanese biotechnology company specializing in the development of blood products derived from human induced pluripotent stem cells (iPSCs). Its primary focus is on creating platelets and red blood cells independent of traditional blood donations.

BrightPath Biotherapeutics Co., Ltd. is a biopharmaceutical company based in Kurume, Japan, specializing in the development of innovative cancer immunotherapy drugs. The company is advancing its lead candidate, ITK-1, a cancer peptide vaccine currently in Phase III clinical trials for the treatment of prostate cancer. Additionally, BrightPath is developing GRN-1201, which is in Phase II trials for non-small cell lung cancer and Phase I trials for melanoma. The company also has research-stage products, including GRN-1301, a neoantigen targeting drug-resistant tumors in non-small cell lung cancer, and iPS-NKT, a therapy utilizing induced pluripotent stem cell-derived NKT cells. Founded in 2003, BrightPath Biotherapeutics aims to stimulate potent immune responses to tumor-associated antigens through its peptide vaccine technology.

REGiMMUNE Corporation is a biotechnology company based in Tokyo, Japan, with an additional office in San Francisco, California. Founded in 2006, the company specializes in the discovery and development of immune-regulatory therapeutics aimed at treating severe diseases and disorders related to the immune system. Utilizing its proprietary reVax technology, REGiMMUNE targets immune tolerance by inducing regulatory T cells, which can address a variety of conditions such as Graft versus Host Disease, type 1 diabetes, rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. The company has one clinical-stage compound, RGI-2001, currently in a Phase I/II trial for GvHD associated with hematopoietic stem cell transplantation, and a second product, RGI-3001, in preclinical development for type 1 diabetes. With a pipeline that includes several promising compounds, REGiMMUNE aims to provide innovative treatments that minimize the side effects commonly associated with traditional immunosuppressants.

Founded in Tokyo, Japan in 2007, Ipoca develops a digital platform that connects users with local retail stores, fostering economic revitalization and mobility.

Connectec Japan Corporation specializes in the development of semiconductor and electrical products, focusing on semiconductor chip bonding and low-temperature MEMS chips. Founded in 2009 and headquartered in Myoko, Japan, the company also offers foundry services for semiconductor packaging, alongside technical support for surface mount technology (SMT). Its capabilities extend to providing evaluation, analysis, and reliability testing services, as well as developing small desktop semiconductor assembly equipment. Connectec Japan operates a satellite office in Kyoto and has sales offices in Seoul, South Korea, and Suzhou, China, serving a diverse clientele in various industrial applications.